Sign in

    Arthur Key • H.C. Wainwright & Co.

    Arthur He, CFA, is a Wall Street Analyst at H.C. Wainwright & Co., specializing in equity research with a focus on the general sector and diverse public companies. He covers notable firms including Nvidia (NVDA), Tesla (TSLA), Amazon (AMZN), Alibaba (BABA), Poseida Therapeutics (PSTX), and Gold Resource Corporation (GORO), where he has a recent track record of impactful ratings such as a 269% return on a PSTX buy call and an average return of 17.6% per rating with a 50% success rate across 115 stock recommendations. Arthur He began issuing stock recommendations at H.C. Wainwright in 2023, with no prior publicly documented analyst roles, and currently holds his CFA credential, signaling rigorous financial and ethical standards. His ratings are predominantly Buy recommendations, and he maintains active coverage of 15 stocks with a TipRanks ranking in the top quartile of all Wall Street analysts.

    Arthur Key's questions to Bioatla Inc (BCAB) leadership

    Arthur Key's questions to Bioatla Inc (BCAB) leadership • Q4 2024

    Question

    Arthur Key from H.C. Wainwright & Co. asked about the expected dose level for the upcoming mid-year EpCAM data, whether more patients would be treated in the AXL program, and if the company was open to other strategic options beyond partnering.

    Answer

    Executive Jay Short stated that data from the 300 microgram cohort for EpCAM should be available, with a possibility of higher dose data. He confirmed the intent to add a few more patients to the AXL trial but noted EpCAM is the priority. He also affirmed the company is open to other strategies, such as a partner prioritizing AXL over ROR2, and is always considering backup plans.

    Ask Fintool Equity Research AI